Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
AssigneeBioCryst Pharmaceuticals, Inc.
InventorsYarlagadda Babu, Viral Kansara, Rick McElheny
Life of this patent
Estimating the term…
Abstract
This disclosure is generally in the field of ophthalmic therapies, and more particularly to the treatment of various ocular diseases and conditions by non-surgical administration to the eye of a subject of a drug composition described herein containing a plasma kallikrein inhibitor. Plasma kallikrein inhibitors include avoralstat. The compositions and methods include delivery of a plasma kallikrein inhibitor to the suprachoroidal space (SCS) of the eye.
Claims16
A method for treating an ocular disease or condition in a subject, the method comprising non-surgically administering an effective amount of a drug composition comprising an effective amount of a plasma kallikrein inhibitor to a suprachoroidal space (SCS) of an eye of the subject thereby allowing the plasma kallikrein inhibitor access to an ocular tissue, wherein the plasma kallikrein inhibitor is the sole therapeutic agent present in the drug composition, and wherein the ocular disease or condition is diabetic retinopathy or diabetic macular edema, and wherein the plasma kallikrein inhibitor is a compound of formula IB
- wherein:
- X is CH;
- Y is N;
- R is —CH2═CH2;
- R1 is —OCH3;
- V is C(O)OH;
- R10 is —(CH2)-cyclopropyl;
- and
- R11 is ═O.
Dependencies are inferred from the claim text.